Combination injection or IV administration

What the study did: The researchers assessed whether receiving the monoclonal antibodies casirivimab and imdevimab by injection was associated with reduced hospitalizations and deaths compared to no treatment in patients with COVID-19 and whether the results were similar if they were administered by injection or intravenously. Administration by injection may increase the capacity for outpatient treatment, but its effectiveness is unknown.

Authors: Erin K. McCreary, Pharm.D., of the University of Pittsburgh School of Medicine, is the corresponding author.

To access the study under embargo: Visit our For Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.6920)

Editor’s note: Please see the article for more information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers with free access to the full-text article This link will be live at the time of the embargo http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.6920?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041222

On Open JAMA Network: Open JAMA Network is the new online-only open access general medical journal of the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health fields. Each article is put online for free from the day of its publication.


Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Comments are closed.